{{Rsnum
|rsid=7568458
|Gene=GGCX
|Chromosome=2
|position=85561052
|Orientation=plus
|GMAF=0.494
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=GGCX
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 24.6 | 50.8 | 24.6
| HCB | 13.3 | 46.7 | 40.0
| JPT | 11.4 | 47.7 | 40.9
| YRI | 65.1 | 31.7 | 3.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.3 | 46.7 | 40.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=19436136
|Title=Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status
|OA=1
}}

{{PMID Auto
|PMID=18574025
|Title=The largest prospective warfarin-treated cohort supports genetic forecasting.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}